Lataa...
Overcoming docetaxel resistance in prostate cancer: a perspective review
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with my...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3481557/ https://ncbi.nlm.nih.gov/pubmed/23118808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834012449685 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|